Business Context and Reporting Period
Company: Cara Therapeutics, Inc. (CARA)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2024
Cara Therapeutics is a biopharmaceutical company focused on treating chronic pruritus. Its lead product, KORSUVA (difelikefalin) injection, is approved for moderate-to-severe pruritus associated with chronic kidney disease in hemodialysis patients. In June 2024, the Board of Directors approved a streamlined operating plan to explore strategic alternatives after discontinuing its clinical program for oral difelikefalin in notalgia paresthetica (NP) due to lack of efficacy in the KOURAGE-1 study. This decision triggered a second workforce reduction of approximately 70%.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2024 | Six Months Ended June 30, 2023 |
|---|---|---|---|
| Total Revenue | $991 | $3,126 | $13,098 |
| Net Loss | $(20,016) | $(50,712) | $(58,144) |
| Net Loss Per Share (Basic & Diluted) | $(0.37) | $(0.93) | $(1.08) |
| Operating Cash Flow | N/A | $(42,890) | $(55,063) |
| Cash, Cash Equivalents & Restricted Cash | $50,739 (as of June 30, 2024) | N/A | N/A |
| Marketable Securities | $7,379 (as of June 30, 2024) | N/A | N/A |
| Total Liabilities | $60,897 (as of June 30, 2024) | N/A | N/A |
| Stockholders' Equity | $11,598 (as of June 30, 2024) | N/A | N/A |
Note: Revenue for the three months ended June 30, 2024, consisted entirely of "Other revenue" ($991k) related to non-cash royalty payments remitted to HCR under a royalty sale agreement. Collaborative and commercial supply revenue were zero for the quarter.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 86% year-over-year for the quarter and 76% for the six-month period. This was driven by the cessation of collaborative revenue (profit share from U.S. sales) and commercial supply revenue due to negative net sales reported by partner CSL Vifor, primarily caused by the expiration of the Transition Drug Add-on Payment Adjustment (TDAPA) in April 2024.
- Restructuring Costs: The company recorded $2.6 million in restructuring expenses for the quarter and $5.0 million for the six months ended June 30, 2024, related to workforce reductions (approx. 70% in Q2) and the discontinuation of the NP program. There were no restructuring expenses in the comparable 2023 periods.
- Inventory Write-Down: A $1.5 million loss on inventory write-down was recorded in Q2 2024 due to obsolescence, compared to zero in the prior year.
- Non-Cash Interest: Non-cash interest expense of $1.9 million (Q2) and $3.9 million (YTD) was recognized related to the liability from the sale of future royalties to HCRX Investments Holdco, L.P. (HCR). This item did not exist in 2023.
- Liquidity: Cash and cash equivalents decreased from $51.8 million at year-end 2023 to $49.2 million at June 30, 2024. Marketable securities dropped significantly from $49.0 million to $7.4 million as the company utilized investments to fund operations.
Guidance, Outlook, and Risks
- Strategic Review: Management is exploring strategic alternatives to maximize shareholder value following the discontinuation of the NP clinical program. No specific financial guidance was provided for future periods.
- Liquidity Outlook: Management expects current unrestricted cash, cash equivalents, and marketable securities ($56.6 million total) to be sufficient to fund the streamlined operating plan for at least the next 12 months.
- Revenue Outlook: The company expects no meaningful revenue contribution from KORSUVA injection following the TDAPA expiration. Future revenue is uncertain and dependent on the outcome of the strategic review or potential resumption of development.
- Nasdaq Compliance: The company received a notice from Nasdaq regarding its stock price trading below $1.00 for 30 consecutive days. It was granted an extension until January 27, 2025, to regain compliance. Failure to comply could result in delisting.
- Risks: Key risks include the uncertainty of the strategic review process, potential delisting from Nasdaq, the need for additional capital if development resumes, and the impact of the HCR Agreement which diverts future royalty streams.
Investor Verification Checklist
- Strategic Alternatives: Verify the status of the strategic review process and any potential transactions (merger, acquisition, or liquidation) that may be announced.
- Nasdaq Compliance: Monitor the stock price to ensure it meets the $1.00 minimum bid price requirement for 10 consecutive days before January 27, 2025, to avoid delisting.
- Cash Burn Rate: Assess the sustainability of the $56.6 million cash position against the streamlined operating plan, particularly given the cessation of significant revenue streams.
- HCR Agreement Obligations: Review the terms of the royalty sale agreement with HCR, specifically the repayment obligations and the impact on future cash flows from ex-U.S. royalties.
- Restructuring Completion: Confirm the final costs associated with the 70% workforce reduction and any remaining severance liabilities.